This is an Untapped Market
People In the United States Suffer From Osteoarthritis
14-55
Age Range: Aimed at Younger Patients Suffering from OA
The Growing Hip Preservation Market is worth Billions
Our Technology?
Expertise and Innovation
Sign up for Business News
Questions
About the
Technology?
Expertise and Innovation
Sign up for Business News
News
CytexOrtho on Capital Hill
On May 11th, 2023 Dr Brad Estes, CytexOrtho Co-founder and CEO, traveled to Washington D.C. to sit on a panel about the state of osteoarthritis (OA) in the United States, and the need for additional funding to move scientific advances combating OA to the clinic. The...
Breakthrough Device Designation from the FDA
We are thrilled to announce that we just received a Breakthrough Device Designation from the United States Food and Drug Administration (FDA) for our novel hip cartilage repair technology. The intent of the Breakthrough Devices Program1 is to help patients have...
October Newsletter
The October issue of the CytexOrtho newsletter covers our progression toward clinical trials, discussions with the FDA, and our new CRP award from NIH! If you would like to receive a copy of our future newsletters, be sure to sign up for our mailing lists via the...
News
CytexOrtho on Capital Hill
On May 11th, 2023 Dr Brad Estes, CytexOrtho Co-founder and CEO, traveled to Washington D.C. to sit on a panel about the state of osteoarthritis (OA) in the United States, and the need for additional funding to move scientific advances combating OA to the clinic. The...
Breakthrough Device Designation from the FDA
We are thrilled to announce that we just received a Breakthrough Device Designation from the United States Food and Drug Administration (FDA) for our novel hip cartilage repair technology. The intent of the Breakthrough Devices Program1 is to help patients have...
October Newsletter
The October issue of the CytexOrtho newsletter covers our progression toward clinical trials, discussions with the FDA, and our new CRP award from NIH! If you would like to receive a copy of our future newsletters, be sure to sign up for our mailing lists via the...